New therapeutic agents for the treatment of bone diseases (Q36161232)

12 August 2017

1 reference

title

New therapeutic agents for the treatment of bone diseases (English)

1 reference

12 August 2017

Allan Lipton

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

817-832

1 reference

Osteoporosis and the global competition for health care resources.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Osteoporosis due to cancer treatment: pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Malignant bone pain: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Bisphosphonates: preclinical aspects and use in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Protein prenylation: molecular mechanisms and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Bisphosphonates induce apoptosis in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Oral clodronate in breast cancer patients with bone metastases: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Management of Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Calcitonin and calcitonin receptors: bone and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Clinical, Biochemical and Histological Observations on the Effect of Porcine Calcitonin in Paget's Disease of Bone*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

A comparison of the acute effects of subcutaneous and intranasal calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Effects of five daily 1 h infusions of alendronate in Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Measurement of urinary excretion of nonisomerized and ?-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Ibandronate in the treatment of prostate cancer associated painful osseous metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Osteonecrosis of the jaws associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Bisphosphanates and Oral Cavity Avascular Bone Necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Current concepts of the management of dental extractions for patients taking warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Safety and convenience of a 15-minute infusion of zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Role of bisphosphonates in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

Bisphosphonate therapy in the oncology setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14712598.5.6.817

21 January 2018

Identifiers

DOI

10.1517/14712598.5.6.817

1 reference

12 August 2017

1 reference